Results 261 to 270 of about 466,117 (305)
Some of the next articles are maybe not open access.
THE RATIONALE FOR ENDOCRINE THERAPY
Acta Obstetricia et Gynecologica Scandinavica, 1989There are three major types of peritoneal endometriotic implant as distinguished by their laparoscopic and morphological characteristics; the microscopic or epithelial‐type plaque, the vesicular and papular type and the fibrotic, nodular type. Fluctuations in hormone levels during the menstrual cycle and throughout hormonal therapy have differential ...
openaire +3 more sources
Seminars in Breast Disease, 2004
The modern era of neoadjuvant endocrine therapy was developed with tamoxifen in the 1980s. Trials showed useful downstaging to avoid mastectomy, but long term results showed that this could be used before but not instead of surgery. Recently neoadjuvant aromatase inhibitors have been shown to be superior to tamoxifen.
openaire +1 more source
The modern era of neoadjuvant endocrine therapy was developed with tamoxifen in the 1980s. Trials showed useful downstaging to avoid mastectomy, but long term results showed that this could be used before but not instead of surgery. Recently neoadjuvant aromatase inhibitors have been shown to be superior to tamoxifen.
openaire +1 more source
2010
Adjuvant endocrine therapy is a mainstay of treatment for women with hormone-receptor (estrogen-receptor and/or progesterone-receptor) expressing breast cancers. Extensive clinical trials over decades have demonstrated compelling improvements in overall survival and disease-free survival with use of adjuvant endocrine therapy. Along with implementation
openaire +1 more source
Adjuvant endocrine therapy is a mainstay of treatment for women with hormone-receptor (estrogen-receptor and/or progesterone-receptor) expressing breast cancers. Extensive clinical trials over decades have demonstrated compelling improvements in overall survival and disease-free survival with use of adjuvant endocrine therapy. Along with implementation
openaire +1 more source
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Ca-A Cancer Journal for Clinicians, 2022Alexander Shimabukuro-Vornhagen +2 more
exaly